Avadel Pharmaceuticals plc Stock price

Equities

AVDL

US05337M1045

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
15.77 USD -0.94% Intraday chart for Avadel Pharmaceuticals plc -1.44% +11.69%
Sales 2024 * 167M Sales 2025 * 301M Capitalization 1.43B
Net income 2024 * -33M Net income 2025 * 91M EV / Sales 2024 * 8.95 x
Net Debt 2024 * 66.33M Net cash position 2025 * 5.71M EV / Sales 2025 * 4.73 x
P/E ratio 2024 *
-35 x
P/E ratio 2025 *
19.8 x
Employees 154
Yield 2024 *
-
Yield 2025 *
-
Free-Float 39.35%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Avadel Pharmaceuticals plc Presents at UBS Virtual CNS Day 2024, Mar-18-2024 12:30 PM
Craig-Hallum Adjusts Avadel Pharmaceuticals' Price Target to $22 From $20, Maintains Buy Rating MT
HC Wainwright Raises Price Target on Avadel Pharmaceuticals to $25 From $21, Maintains Buy Rating MT
Piper Sandler Raises Price Target on Avadel Pharmaceuticals to $23 From $18, Maintains Overweight Rating MT
Needham Adjusts Avadel Pharmaceuticals' Price Target to $22 From $20, Keeps Buy Rating MT
Oppenheimer Adjusts Avadel Pharmaceuticals Price Target to $29 From $27, Maintains Outperform Rating MT
ADRs End Higher, Renalytix PLC Climbs 41.4% DJ
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday MT
Transcript : Avadel Pharmaceuticals plc, Q4 2023 Earnings Call, Mar 04, 2024
Avadel Pharmaceuticals' Q4 Loss Narrows, Reports Revenue; Shares Gain Premarket MT
Stock Futures Decline Pre-Bell as Traders Await Labor Data; Asia Up, Europe Mixed MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
Avadel Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Tuesday Trading MT
More news
1 day-0.94%
1 week-1.44%
Current month+23.40%
1 month+16.21%
3 months+13.78%
6 months+33.08%
Current year+11.69%
More quotes
1 week
15.70
Extreme 15.7
16.46
1 month
11.82
Extreme 11.82
17.00
Current year
11.82
Extreme 11.82
17.24
1 year
8.00
Extreme 8
17.24
3 years
1.05
Extreme 1.05
17.24
5 years
1.03
Extreme 1.03
17.24
10 years
1.03
Extreme 1.03
26.09
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 17-01-02
Director of Finance/CFO 59 19-12-01
Chief Operating Officer - 14-08-31
Members of the board TitleAgeSince
Director/Board Member 55 18-11-30
Chief Executive Officer 57 17-01-02
Director/Board Member 72 19-12-04
More insiders
Date Price Change Volume
24-03-18 15.77 -0.94% 655,482
24-03-15 15.92 -1.12% 685,709
24-03-14 16.1 +0.12% 887,709
24-03-13 16.08 +0.69% 981,013
24-03-12 15.97 -0.19% 1,440,388

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
15.77 USD
Average target price
22.9 USD
Spread / Average Target
+45.21%
Consensus
  1. Stock
  2. Equities
  3. Stock Avadel Pharmaceuticals plc - Nasdaq